Document Detail


Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
MedLine Citation:
PMID:  23165656     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
INTRODUCTION: Bazedoxifene is a novel selective estrogen receptor modulator (SERM) for the prevention and treatment of osteoporosis. In addition to the therapeutic value of a new agent, evaluation of the cost-effectiveness compared with relevant alternative treatment(s) is an important consideration to facilitate health-care decision making. This study evaluated the cost-effectiveness of bazedoxifene compared with raloxifene for the treatment of postmenopausal women with osteoporosis. MATERIAL AND METHODS: The cost-effectiveness of treatment for 3-years with bazedoxifene was compared with raloxifene using an updated version of a previously validated Markov microsimulation model. Analyses were conducted from a Belgian healthcare payer perspective and, the base-case population was women (aged 70 years) with bone mineral density T-score ≤-2.5. The effects of bazedoxifene and raloxifene on fracture risk were derived from the 3-year results of a randomized, double-blind, placebo- and active-controlled study, including postmenopausal women with osteoporosis. RESULTS: The cost-effectiveness analysis based on efficacy data from the overall clinical trial indicated that bazedoxifene and raloxifene were equally cost-effective. When the results were examined based on the subgroup analysis of women at higher risk of fractures, bazedoxifene was dominant (lower cost for higher effectiveness) compared with raloxifene in most of the simulations. Sensitivity analyses confirmed the robustness of the results, which were largely independent of starting age of treatment, fracture risk, cost and disutility. In addition, when the cost of raloxifene was reduced by half or when incorporating the raloxifene effects on reducing breast cancer, bazedoxifene remained cost-effective, at a threshold of €35,000 per quality-adjusted life-years gained, in 85% and 68% of the simulations, respectively. CONCLUSION: Under the assumption of improved anti-fracture efficacy of bazedoxifene over raloxifene in women with high risk of fractures, this study suggests that bazedoxifene can be considered cost-effective, and even dominant, when compared with raloxifene in the treatment of postmenopausal osteoporotic women. © 2012 American Society for Bone and Mineral Research.
Authors:
Mickael Hiligsmann; Wafa Ben Sedrine; Jean-Yves Reginster
Related Documents :
24829126 - Short qt in a cohort of 1.7 million persons: prevalence, correlates, and prognosis.
25012606 - Are there gender differences in the emotional intelligence of resident physicians?
23621746 - The impact of a culturally tailored patient navigator program on cervical cancer preven...
15878296 - Fear-avoidance beliefs and pain coping strategies in relation to lower back problems in...
9395816 - The epidemiology of obesity: a review.
1855826 - Microbiological evaluation of female patients in std clinics.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-19
Journal Detail:
Title:  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research     Volume:  -     ISSN:  1523-4681     ISO Abbreviation:  J. Bone Miner. Res.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610640     Medline TA:  J Bone Miner Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 American Society for Bone and Mineral Research.
Affiliation:
Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; Departments of Internal Medicine and of Clinical Epidemiology & Medical Technology Assessment, CAPHRI School for Primary Care and Public Health, Maastricht University, the Netherlands. m.hiligsmann@ulg.ac.be.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanistic aspects of the linear stabilization of non-stationary electrochemical oscillations.
Next Document:  Stratum Corneum Drying Drives Vertical Compression and Lipid Organization and Improves Barrier Funct...